Skip to main content
Sirona Biochem Corp. logo

Sirona Biochem Corp. — Investor Relations & Filings

Ticker · SRBCF ISIN · CA82967M1005 LEI · 549300CQE1Q87IG6W210 TSXV Real estate activities
Open in API
Filings indexed 367 across all filing types
Latest filing 2023-05-03 Regulatory Filings
Country CA Canada
Listing TSXV SRBCF

About Sirona Biochem Corp.

https://www.sironabiochem.com/

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery firm utilizing a proprietary platform technology to develop novel compounds. Through its wholly-owned French subsidiary, TFChem, the company specializes in stabilizing carbohydrate molecules, often via fluorination chemistry, to enhance their efficacy and safety for medical and cosmetic applications. Sirona Biochem's business strategy involves licensing or selling its patented compounds, such as the anti-aging and anti-wrinkle molecule GlycoProteMim™ (TFC-1326), to leading global pharmaceutical and cosmetic companies in exchange for up-front fees, milestone payments, and ongoing royalties.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Sirona Biochem will present its anti-aging technology at the BIO 2023 conference. It describes the product, the event details, and company background but does not contain any financial data, regulatory filings, or detailed financial reports. It is an announcement of a presentation at a conference, not the presentation material itself or a financial report. Therefore, it fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement and does not fit other specific categories.
2023-05-03 English
Material change report - English.pdf
Regulatory Filings
2023-04-27 English
News release - English.pdf
Regulatory Filings
2023-04-25 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the closing of an oversubscribed convertible debenture financing by Sirona Biochem Corp. It details the terms of the financing, including the amount raised, the nature of the debenture units, interest rates, conversion rights, and use of proceeds. There is no financial statement or comprehensive financial report included. The document is an update on a capital raising event, not a full financial report or earnings release. Therefore, it fits the category of Capital/Financing Update (CAP). The document length (7204 characters) and content confirm it is a detailed announcement of financing activity rather than a brief notice or regulatory filing.
2023-04-20 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a certification statement by the CEO regarding the review and fair presentation of the interim financial report and interim MD&A for the period ended January 31, 2023. It is a Form 52-109FV2, which is a certification of interim filings for a venture issuer. The document does not contain the actual interim financial statements or substantive financial data but is an attestation about those filings. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is short (3010 characters), and it is clearly a certification letter rather than a full interim report.
2023-03-29 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a certification by the CFO of Sirona Biochem Corp. regarding the interim financial report and interim MD&A for the period ended January 31, 2023. It is a Form 52-109FV2 Venture Issuer Basic Certificate, which certifies the accuracy and fair presentation of the interim filings but does not contain the actual financial data or the interim report itself. The document is short (2957 characters) and primarily an officer certification. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS) rather than as the interim report (IR) itself.
2023-03-29 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.